Kintara Therapeutics, Inc. - KTRA STOCK NEWS

Kintara Therapeutics (Nasdaq: KTRA), based in San Diego, is presenting at the Biotech Showcase Conference in San Francisco on January 10, 2023, at 11:30 am PST. CEO Robert E. Hoffman will discuss the company's innovative therapies for solid tumors, including VAL-083 and REM-001 Therapy, targeting unmet medical needs in cancer treatment. VAL-083 is in a registrational clinical trial for glioblastoma, while REM-001 has shown an 80% complete response in cutaneous metastatic breast cancer but is currently paused to conserve resources. More details are available on Kintara's website.

Kintara Therapeutics (KTRA) announced receiving Orphan Drug Designation (ODD) from the FDA for its drug VAL-083, aimed at treating diffuse intrinsic pontine glioma (DIPG), a rare childhood brain cancer. The ODD offers development incentives such as tax credits and seven-year marketing exclusivity upon FDA approval. Kintara's CEO, Robert E. Hoffman, emphasized the importance of this designation in advancing VAL-083 alongside their lead indication of glioblastoma. Kintara also has ongoing clinical programs for other cancer therapies, including REM-001 for cutaneous metastatic breast cancer.

Kintara Therapeutics, a biopharmaceutical firm, will have its President and CEO, Robert E. Hoffman, participate in the RHK Capital Disruptive Growth Conference in New York City on December 5, 2022, at 2:40 pm ET. The event will bring together executives and institutional investors to discuss growth-oriented companies. Kintara is developing innovative cancer therapies, including VAL-083 for glioblastoma and REM-001 for metastatic breast cancer. VAL-083 is currently in a registrational Phase 2/3 trial under the GBM AGILE Study.

Kintara Therapeutics, Inc. (KTRA) announced it has regained compliance with Nasdaq's minimum bid price requirement. A notice received on November 29, 2022, confirmed that KTRA's closing stock price exceeded $1.00 for 10 consecutive days. The company specializes in developing cancer therapies, with ongoing clinical trials for VAL-083 and REM-001 Therapy, targeting glioblastoma and cutaneous metastatic breast cancer respectively. Kintara has paused the REM-001 program to conserve cash, while VAL-083 is advancing through the GBM AGILE Study for regulatory support.

Kintara Therapeutics (KTRA) has received Fast Track Designation from the FDA for its REM-001 Therapy aimed at treating cutaneous metastatic breast cancer (CMBC). The therapy has shown an impressive 80% complete response rate in previous trials among patients who had received prior treatment. Kintara, which is currently seeking funding, plans to restart clinical studies to advance this therapy. The Fast Track Designation allows for enhanced FDA access and potential expedited review processes, which may accelerate product approval timelines.

Kintara Therapeutics (Nasdaq: KTRA) presented three posters at the 2022 Society for Neuro-Oncology Annual Meeting, held from November 16-20 in Tampa, Florida. Key highlights include:

• A Phase 2 study showing that two patients with newly-diagnosed GBM survived 53 and 35 months post-treatment with VAL-083.
• A case report on a patient with recurrent ependymoma who remains stable 18 months after treatment.
• Data from 14 recurrent GBM patients revealing no significant hematological adverse events with VAL-083.

Kintara aims to advance VAL-083 through the GBM AGILE study.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) announced a 1-for-50 reverse stock split effective November 11, 2022, to meet Nasdaq's minimum bid price requirement of $1.00. The number of outstanding shares will decrease from approximately 80.8 million to about 1.6 million, with authorized shares reducing from 275 million to 5.5 million. This move aims to ensure continued trading on Nasdaq. The adjusted shares will begin trading on November 14, 2022. No stockholder approval was required, and fractional shares will be rounded up.

Kintara Therapeutics (Nasdaq: KTRA) reported its fiscal 2023 first quarter results, ending September 30, 2022. The company paused the REM-001 program to save approximately $3 million, redirecting funds to the VAL-083 registrational study in glioblastoma. Kintara's cash and equivalents totaled $7.1 million as of September 30, with a net loss of $4.6 million or $0.07 per share, improved from a $6 million loss in Q1 2022. The company has also entered a $20 million purchase agreement with Lincoln Park Capital, receiving $1.9 million to date.

Kintara Therapeutics (Nasdaq: KTRA) has paused its REM-001 program targeting Cutaneous Metastatic Breast Cancer (CMBC) to conserve approximately $3 million through 2023. This decision enables funding for the ongoing VAL-083 international registrational study for glioblastoma. Despite the pause, the company aims to explore future funding options, including grants. Kintara continues to anticipate announcing top-line data for VAL-083 from the GBM AGILE study by the end of 2023, highlighting its commitment to addressing unmet medical needs in oncology.